{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"70","upperLimit":"96","value":"87"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Overall response rate is percentage of participants with complete (CR), very good partial (VGPR), partial (PR), or minimal response (MR) as best response during treatment.\n\nCR:\n\n* No serum monoclonal IgM protein by immunofixation\n* Normal IgM level\n* Complete resolution of extramedullary disease, i.e., lymphadenopathy and splenomegaly if present at baseline\n* Morphologically normal bone marrow aspirate and trephine biopsy\n\nVGPR:\n\n* Monoclonal IgM protein is detectable ≥90% reduction in IgM level from baseline\n* Complete resolution of extramedullary disease, i.e., lymphadenopathy/splenomegaly if present at baseline\n* No new signs/symptoms of active disease\n\nPR:\n\n* Monoclonal IgM protein is detectable ≥50% but \\<90% reduction in IgM level from baseline\n* Reduction in extramedullary disease\n* No new signs/symptoms of active disease\n\nMR:\n\n* Monoclonal IgM protein is detectable ≥25% but \\<50% reduction in IgM level from baseline\n* No new signs/symptoms of active disease","dispersionType":"95% Confidence Interval","groups":[{"description":"Combination of everolimus \\& rituximab with bortezomib for 6 cycles\n\nEverolimus 10 mg: Taken orally on a daily basis x 28 days (1 cycle)\n\nRituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only (1 cycle = 28 days)\n\nBortezomib 1.6 mg/m\\^2: Given intravenously on days 1, 8 and 15 of every cycle (1 cycle = 28 days)","id":"OG000","title":"Phase II"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 6 cycles (Day 168)","title":"Phase II Overall Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}